tau imaging news adds a new scan option for Alzheimer's workups, where tau is a brain protein that forms memory-linked tangles. Patients can compare options by starting with blood testing, then discussing tau PET only if staging would change care.
On Aug. 14, 2026, FDA approved Lantheus Tauklarify for brain PET to identify tau tangle pathology in adults with cognitive impairment evaluated for Alzheimer's disease, according to Lantheus Holdings the FDA approval notice. The approval gives primary care doctors a clearer referral path when the diagnosis remains uncertain after initial testing.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the new tau scan does
- Where blood tests fit first
- How to read accuracy and limits
- What to ask your primary care doctor
What the new tau scan does
Tauklarify uses florquinitau F 18, also called MK-6240, to highlight tau neurofibrillary tangles during a brain PET scan. A trained reader reviews the scan pattern to judge whether Alzheimer-related tau pathology is present. It is ordered for Alzheimer's evaluation, not for general memory screening. The May 28, 2026 HEAD study tested MK-6240 against flortaucipir in 682 people with paired scans, according to MedicalXpress reporting University of Pittsburgh/Lancet research the HEAD study report.
MK-6240 found medial-temporal tau in 15% of cognitively unimpaired amyloid-positive people, versus 6% for flortaucipir. It also separated Alzheimer-related impairment more sharply, with an AUC of 0.93 versus 0.86. Earlier detection matters because medial-temporal tau can appear before clear daily symptoms. A more sensitive signal may help specialists place a patient earlier on the Alzheimer's continuum. It does not by itself prove that tau causes current symptoms.
Where blood tests fit first
For most primary care patients, blood testing remains the lower-burden first step. A blood draw is simpler than PET, requires no radiation, and can be done in a clinic visit. The result helps decide whether referral, watchful follow-up, or additional confirmation makes sense. On Aug. 24, 2026, FDA cleared Roche Elecsys Phospho-Tau 217P Plasma for ages 55 and older with cognitive symptoms, according to Roche the clearance announcement.
Roche describes it as the first single-biomarker blood test supporting both rule-in and rule-out of amyloid pathology across primary and specialty care. By August 2026, FDA-cleared blood options had grown to four, expanding choices for initial triage. The Alzheimer's Association guideline from July 2025 sets performance tiers for this use. Tests with at least 90% sensitivity and 75% specificity may triage patients, while only tests with at least 90% sensitivity and 90% specificity may replace amyloid PET or spinal-fluid testing in cognitively impaired specialty-care patients. Patients can ask which tier their offered test meets and what a borderline result would trigger next.
How to read accuracy and limits
Tau PET reading is strong but not perfect. NeurologyLive reports two blinded-read trials with five readers showing 68% to 88% positive agreement and 93% to 99% negative agreement against reference standards. Inter-reader agreement was high, with kappa values of 0.92 and 0.86, and safety data covered 1,734 subjects. Those numbers mean negative reads are usually consistent, while some positive cases remain harder to call. Lantheus prescribing information warns that a negative scan does not exclude tau pathology.
It also limits approved use to Alzheimer's evaluation because safety and effectiveness for other tau diseases are unestablished. Radiation exposure is another practical limit. Lantheus prescribing information notes that PET radiation adds to cumulative exposure and long-term cancer risk. Patients with prior frequent imaging, pregnancy concerns, or complex medical histories should review total radiation burden before scheduling. The scan makes most sense when staging or treatment eligibility would change.
What to ask your primary care doctor
Swedish real-world data reported at AAIC 2026 found family physicians made the correct Alzheimer's diagnosis in 65% of cases before blood results and 93% after, close to specialists at 94%, according to a NeurologyLive interview with the Alzheimer's Association the interview on primary care results. The study included more than 1,300 patients and 165 physicians. The finding supports starting the conversation in primary care rather than waiting for a specialist.
Bring symptoms, timing, medications, sleep changes, and a list of daily tasks that have become harder. Ask whether a validated blood test is available locally, what it rules in or out, and how soon results return. If referral is discussed, ask what new information tau PET would add. If uncertainty remains after blood work and the next choice would alter care, ask for a documented plan naming the test, its purpose, and the decision it will guide.
- Do my symptoms and age fit the blood test now cleared for primary care use.
- Would a positive or negative blood result change referral, monitoring, or treatment access.
- Would tau PET staging affect diagnosis, trial eligibility, or planned therapy.
- What are the radiation, cost, travel, and follow-up steps for PET versus repeat blood monitoring.
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: How Primary Care Patients Can Compare Testing Options
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: How Primary Care Patients Can Compare Testing Options
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: Questions Primary Care Patients Can Bring to a Clinician
